Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 5/1997

Content (14 Articles)

ORIGINAL ARTICLE

Combined intravenous and oral mesna in outpatients treated with ifosfamide

Marshall P. Goren, Linda M. McKenna, Thomas L. Goodman

ORIGINAL ARTICLE

Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion

L. D. Nord, R. L. Stolfi, A. A. Alfieri, G. Netto, V. Reuter, S. S. Sternberg, J. R. Colofiore, J. A. Koutcher, D. S. Martin

ORIGINAL ARTICLE

Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells

Laurent Poulain, François Sichel, Hubert Crouet, François Bureau, Pascal Gauduchon, Marc Gignoux, Jean-Yves Le Talaër

ORIGINAL ARTICLE

Urinary stability of carboxycyclophosphamide and carboxyifosfamide, two major metabolites of the anticancer drugs cyclophosphamide and ifosfamide

Claire Joqueviel, Véronique Gilard, Robert Martino, Myriam Malet-Martino, Ulf Niemeyer

ORIGINAL ARTICLE

Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft

C. Bradley Hare, Gertrude B. Elion, O. Michael Colvin, Francis Ali-Osman, Owen W. Griffith, William P. Petros, Stephen Keir, Susan L. Marcelli, Darell D. Bigner, Henry S. Friedman

ORIGINAL ARTICLE

Pharmacokinetics of doxorubicin and epirubicin in mice during chlorpromazine-induced hypothermia

L. Lundgren-Eriksson, A. Carlsson, S. Eksborg, W. Ryd, R. Vesanen, R. Hultborn

ORIGINAL ARTICLE

Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer

Vincent A. Miller, James R. Rigas, William P. Tong, Janice R. Reid, Katherine M. W. Pisters, Stefan C. Grant, Robert T. Heelan, Mark G. Kris

ORIGINAL ARTICLE

A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene

Fumihiko Narasaki, Mikio Oka, Minoru Fukuda, Reiji Nakano, Koki Ikeda, Hiroshi Takatani, Kenji Terashi, Hiroshi Soda, Osamu Yano, Tsuyoshi Nakamura, L. Austin Doyle, Takashi Tsuruo, Shigeru Kohno

SHORT COMMUNICATION

Digitonin enhances the efficacy of carboplatin in liver tumour after intra-arterial administration

P. G. Lindnér, Dennis Heath, Stephen B. Howell, Peter L. Naredi, Larsolof R. Hafström

CLINICAL TRIAL REPORT

Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity

Steinar Aamdal, Uta Bruntsch, Jean Kerger, Jaap Verweij, Wim Bokkel Huinink, Jantien Wanders, Ram Rastogi, Hillary R. Franklin, Stan B. Kaye

SHORT COMMUNICATION

Salivary drug monitoring of irinotecan and its active metabolite in cancer patients

Toshiaki Takahashi, Y. Fujiwara, Hidetaka Sumiyoshi, Takeshi Isobe, Naoki Yamaoka, Michio Yamakido

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine